M. Ballabio

TL;DR: The hypothesis that neuroactive steroids might represent a new therapeutic strategy for peripheral neuropathy is proposed.

TL;DR: Data indicates that neuroactive steroids stimulate the expression of two important proteins of the myelin of peripheral nerves, the glycoprotein P0 (P0) and the peripheral myelin protein 22 (PMP22), suggesting that these molecules may represent an interesting new therapeutic approach to maintain peripheral nerve integrity during neurodegenerative events.

TL;DR: It is demonstrated for the first time that GABAB receptor isoforms are specifically localized in the rat Schwann cell population of the sciatic nerve, and exposure of cultured Schwann cells to (–)‐baclofen inhibits their proliferation and reduces the synthesis of specific myelin proteins.

TL;DR: It is demonstrated that in the peripheral nervous system (PNS), the sciatic nerve and myelin-producing Schwann cells express both GABAA and GABAB receptors, and a cross-interaction within the GABAergic receptor system is suggested, at least in the myelinating cells of the PNS.

TL;DR: Data obtained clearly indicate that neuroactive steroids are able to reduce aging-associated morphological abnormalities of myelin and aging- associated myelin fiber loss in the sciatic nerve.